Assistance with generation of a tailored Biomarker Strategy Plan (BSP) for your research programs. As with current practices in large Pharma, a BSP documents the key strategies associated with a program and further acts as management tool in the implementation, coordination, tracking and review of such strategies from early pre-clinical through to proof of concept.

Peer review of biomarker data or a current biomarker study plan / strategy.  Through our extensive experience of implementing biomarker plans and reviewing biomarker study data, we can peer review your current plans / data to ensure best interpretation, define clear decision making and improve future planning.

Guidance on the inclusion / presentation of biomarker data within data packages required during out-licensing discussions with large Pharma. Large Pharma now expect a robust biomarker strategy and/or data as part of an IP package to support a licensing deal. OracleBio can help advise on the presentation of biomarker strategies and/or data within such documents in a format that aligns with current practices within large Pharma.